Co-Founders: Annette King, Jenny Sutton & Mark Wales
Scale: Penelope Lewin, Vicky Papachristos
Galileo Platforms (Galileo) is a B2B technology company serving the insurance sector. Using blockchain technology, Galileo connects participants in the retail insurance ecosystem to serve their clients in real-time, using one single source of truth about that client and their contracts. The ecosystem participants include distributors, insurers, reinsures, other service providers such as medical providers, car repair shops, airlines, builders and payment gateways.
TrademarkVision is at the forefront of a fundamental shift in the trademark and brand protection markets. The Company’s patent-pending image recognition system is quickly changing how trademarks are established and protected by their owners.
THERIGHT.FIT is an online marketplace that directly connects creative talent with clients, without the need for a traditional agency. It’s a community of influencers, bloggers, models, actors, photographers, makeup artists, fashion stylists, and more, all in one place.
Born out of the events industry in 2010, ShowGizmo Ltd provides premier apps for events in every industry. The company continually improves and innovates event technology making the experience of managing events easier and more seamless.
Scale: Lynne Thornton (Board Director) & Lisa Hennessy (Board Director)
FirstStep is a mobile app that lets Australian automatically invest their loose change from everyday electronic purchases into a diversified group of exchange-traded funds (ETFs) based on their risk appetite.
Founded in 2014, Emily Crisps set out with the aim to provide health-conscious consumers with the opportunity to indulge in ‘guilt-free’ snacking. Growing 500% year on year and making significant in-roads in the healthy snacking sector with over 8,000 distribution points across the UK and overseas to date.
Scale: Jenny Petering (Director of Australian subsidiary)
Cognition Therapeutics (“CogRx”) is a clinical stage pharmaceutical company working on the discovery and development of small molecule therapeutics acting on novel targets to halt disease progression and improve symptoms in neurodegenerative disorders.